Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Autolus Therapeutics (AUTL) Misses Q1 EPS by 2c, Misses on Revenue; Offers FY26 Revenue Guidance
May 14, 2026 7:08 AM EDTAutolus Therapeutics (NASDAQ: AUTL) reported Q1 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $26.22 million versus the consensus estimate of $26.27 million.
GUIDANCE:
Autolus Therapeutics sees FY2026 revenue of $120-135 million, versus the consensus of... More
